A government owned investment firm was considering an investment in a small biopharma company developing a therapeutic monoclonal antibody against a novel immuno-oncology target.  Alacrita was asked to assist in a due diligence exercise.


Alacrita's immuno-oncology expert conducted the following activities:

  • Reviewed non-clinical data, FIH protocol, clinical development plan and investigator brochure;
  • Reviewed literature on the novel target;
  • Interviewed company executives; and
  • Provided a written overall evaluation and summary of the scientific, clinical and regulatory risks and opportunities in the context of industry benchmark probabilities of success.

The target company successfully raised its Series B investment.

If we can assist you with a life science consulting project, please contact us.

Related Case Studies